Roche is teaming up with Eli Lilly and Company (Lilly) to support the development of its Elecsys Amyloid Plasma Panel (EAPP) blood test which has been designed by the former to enable the earlier diagnosis of Alzheimer’s disease. According to Roche, to deal with the strain that Alzheimer’s disease has on healthcare systems, it is […]
Eli Lilly and Company (Lilly) has completed its previously announced deal worth up to $1.04 billion of US gene therapy company Prevail Therapeutics. The US pharma giant said that the deal gives it a new modality for drug discovery and development. Furthermore, it will extend its research efforts via the creation of a gene therapy […]
Eli Lilly and Company (Lilly) has signed a deal worth up to $1.04 billion to acquire Prevail Therapeutics, a US gene therapy company engaged in developing disease-modifying AAV9-based gene therapies for neurodegenerative diseases. According to the US pharma giant, the acquisition will set up a new modality for drug discovery and development. It will also […]
Lilly acquisition of Disarm Therapeutics : Eli Lilly and Company (Lilly) has agreed to acquire Disarm Therapeutics, a biotech company based in Cambridge, Massachusetts, which is focused on developing a new class of disease-modifying treatments for patients with axonal degeneration. As per the terms of the deal, Lilly will pay an upfront payment of $135 […]
Reyvow CENTURION trial results : Eli Lilly and Company (Lilly) said that its migraine drug Reyvow (lasmiditan) has met the co-primary endpoint of a phase 3 clinical trial called CENTURION by delivering pain freedom from migraine attacks at 60 minutes and up to 48 hours. According to the US pharma giant, adults who were given Reyvow […]